Pharmacogenomics in bladder cancer

Urologic Oncology
Garrett M Dancik, Dan Theodorescu

Abstract

Bladder cancer is a common cancer worldwide. For patients presenting with muscle-invasive disease, the 5-year survival rate is approximately 50%. Cisplatin-based combination chemotherapy is recommended in the neoadjuvant setting before cystectomy and is also the first line in the metastatic setting. However, the survival benefit of such therapy is modest. The identification of pharmacogenomic biomarkers would enable the rational and personalized treatment of patients by selecting those patients that would benefit most from such therapies sparing others the unnecessary toxicity. Conventional therapies would be recommended for an expected responder, whereas a nonresponder would be considered for alternative therapies selected on the basis of the individual's molecular profile. Although few effective bladder cancer therapies have been introduced in the past 30 years, several targeted therapies against the molecular drivers of bladder cancer appear promising. This review summarizes pharmacogenomic biomarkers that require further investigation or prospective evaluation or both, and publicly available tools for drug discovery and biomarker identification from in vitro data.

References

Aug 29, 2003·The New England Journal of Medicine·H Barton GrossmanE David Crawford
Nov 18, 2004·Journal of the National Cancer Institute·Richard D KennedyD Paul Harkin
Feb 12, 2005·Lancet·John P A Ioannidis
Apr 9, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ryo TakataYusuke Nakamura
Jun 9, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jan LehmannUNKNOWN AUO-AB 05/95
Aug 17, 2005·Medical Principles and Practice : International Journal of the Kuwait University, Health Science Centre·Y A Luqmani
Apr 14, 2006·Neoplasia : an International Journal for Oncology Research·Z WuD Theodorescu
Nov 7, 2006·Cancer Treatment Reviews·Cara A Rabik, M Eileen Dolan
Feb 20, 2007·Molecular Cancer Therapeutics·Dmytro M HavaleshkoDan Theodorescu
Aug 2, 2007·Proceedings of the National Academy of Sciences of the United States of America·Jae K LeeDan Theodorescu
Aug 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anne B AlsTorben F Orntoft
Aug 21, 2007·Cancer Treatment Reviews·Lucy Gossage, Srinivasan Madhusudan
Jun 23, 2010·CA: a Cancer Journal for Clinicians·Bruce L JacobsJames E Montie
Jul 7, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A FontR Rosell
Aug 4, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Walter M StadlerRichard J Cote
Aug 5, 2011·Current Opinion in Urology·Yuanbin RuDan Theodorescu
May 12, 2012·Advanced Drug Delivery Reviews·Yuri G AnissimovMichael S Roberts
Aug 25, 2012·European Urology·Cora N SternbergUNKNOWN International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012
Nov 15, 2012·Pharmacogenomics·Peter H O'Donnell

❮ Previous
Next ❯

Citations

Sep 23, 2016·Chemical Research in Toxicology·Tiffany M ScharadinPaul T Henderson
Jul 27, 2017·Pharmacogenomics·Tahlita Cm Zuiverloon, Dan Theodorescu
Jun 17, 2015·Molecular Cancer Research : MCR·Jonathan HenselDan Theodorescu
Jun 18, 2016·Cancer Research·Neeraj AgarwalDan Theodorescu
Dec 30, 2020·Genetic Testing and Molecular Biomarkers·Chuanbing XuDongfang Hao
Dec 4, 2020·Nature Reviews. Cancer·Linda TranDan Theodorescu
Dec 4, 2020·International Journal of Molecular Sciences·Konstantinos KoutsoukosMeletios-Athanasios Dimopoulos

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Related Papers

Anti-cancer Agents in Medicinal Chemistry
Simone CarradoriGiovanni Battista Di Pierro
Journal of the National Comprehensive Cancer Network : JNCCN
Sumanta K PalElizabeth R Plimack
Expert Review of Anticancer Therapy
Marc A Dall'EraChong-Xian Pan
Expert Review of Anticancer Therapy
Amy Q LeiChong-xian Pan
© 2021 Meta ULC. All rights reserved